{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:07:32Z","timestamp":1788368852193,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,2,5]],"date-time":"2007-02-05T00:00:00Z","timestamp":1170633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclic administration of rifaximin in association with dietary fibre achieves symptomatic relief in uncomplicated diverticular disease (DD) by means of a still undefined mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the effects of a combination of rifaximin and fibre on both hydrogen production by intestinal microflora and oro\u2010anal transit time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a controlled, double\u2010blind crossover trial, 64 patients with uncomplicated DD were given bran (20\u2003g\/day) and randomly treated with rifaximin (1200\u2003mg\/day) or a placebo for 14\u2003days. Evaluation was based on clinical status, breath test, oro\u2010anal transit time and faecal weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The global symptomatic score was significantly reduced after rifaximin (7.1\u2003\u00b1\u20034.1 to 4.1\u2003\u00b1\u20033.3; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005) but not after placebo (6.8\u2003\u00b1\u20033.8 to 6.1\u2003\u00b1\u20033.5). Hydrogen production significantly increased after placebo from 198\u2003\u00b1\u2003134 to 267\u2003\u00b1\u2003161\u2003ppm\/min, while Rifaximin reduced it from 222\u2003\u00b1\u2003187 to 166\u2003\u00b1\u2003131\u2003ppm\/min (<jats:italic>P<\/jats:italic>\u2003=\u20030.05). The total oro\u2010anal transit time decreased from 56.1\u2003\u00b1\u200328.2 to 51.3\u2003\u00b1\u200328.0\u2003h in placebo and from 54.4\u2003\u00b1\u200331.9 to 45.1\u2003\u00b1\u200332.4\u2003h (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) in rifaximin\u2010treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The administration of rifamixin improves the benefits of dietary fibre in uncomplicated DD by preventing its bacterial degradation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03266.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T11:03:18Z","timestamp":1279882998000},"page":"771-779","source":"Crossref","is-referenced-by-count":56,"title":["Interaction between rifaximin and dietary fibre in patients with diverticular disease"],"prefix":"10.1111","volume":"25","author":[{"given":"R.","family":"D'INC\u00c0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"POMERRI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"VETTORATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"DAL PONT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"DI LEO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"FERRONATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"MEDICI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C.","family":"STURNIOLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,2,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2002.0328"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02896.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421040-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15597-9"},{"key":"e_1_2_6_6_2","first-page":"1","article-title":"Colonic diverticular disease","volume":"14","author":"Simpson J","year":"2005","journal-title":"Clin Evid"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(02)90228-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92112-2"},{"key":"e_1_2_6_9_2","first-page":"49","article-title":"Influence on symptoms and transit\u2010time of Vi\u2010SiblinR in diverticular disease","volume":"500","author":"Ewerth S","year":"1980","journal-title":"Acta Chir Scand Suppl"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6276.1629-d"},{"key":"e_1_2_6_11_2","first-page":"128","article-title":"Treatment of diverticular disease","volume":"79","author":"Weinreich J","year":"1982","journal-title":"Scand J Gastroenterol Suppl"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089780"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.1.55"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i18.2773"},{"key":"e_1_2_6_15_2","first-page":"452","article-title":"Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group","volume":"24","author":"Papi C","year":"1992","journal-title":"Ital J Gastroenterol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-002-0396-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00348.x"},{"key":"e_1_2_6_18_2","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double\u2010blind, randomized, placebo\u2010controlled study","volume":"98","author":"Pimentel M","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-8-200610170-00004"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00458.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90313-1"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(86)90686-4"},{"key":"e_1_2_6_23_2","first-page":"147","article-title":"Breath hydrogen (H2) response to carbohydrate malabsorption after exercise","volume":"102","author":"Payne DL","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/29.11.1980"},{"key":"e_1_2_6_25_2","first-page":"798","article-title":"Modification of the breath hydrogen test: increased sensitivity for the detection of carbohydrate malabsorption","volume":"100","author":"Kotler DP","year":"1982","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02065421"},{"key":"e_1_2_6_27_2","first-page":"1632","article-title":"Preventing diverticular disease. Review of recent evidence on high\u2010fibre diets","volume":"48","author":"Aldoori W","year":"2002","journal-title":"Can Fam Physician"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i7.1385"},{"issue":"1","key":"e_1_2_6_29_2","first-page":"141","article-title":"A role for inflammation in irritable bowel syndrome?","volume":"51","author":"Barbara G","year":"2002","journal-title":"Gut"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12489-0"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999409110484"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.1.55"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03266.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03266.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:30:15Z","timestamp":1697232615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03266.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,5]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03266.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03266.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,5]]}}}